Protective activity of Vi capsular polysaccharide vaccine against typhoid fever (Q40792174)

23 September 2017

title

Protective activity of Vi capsular polysaccharide vaccine against typhoid fever (English)

1 reference

23 September 2017

1 reference

K P Klugman

1

1 reference

23 September 2017

I T Gilbertson

2

1 reference

23 September 2017

H J Koornhof

3

1 reference

23 September 2017

J B Robbins

4

1 reference

23 September 2017

R Schneerson

5

1 reference

23 September 2017

D Schulz

6

1 reference

23 September 2017

M Cadoz

7

1 reference

23 September 2017

J Armand

8

1 reference

23 September 2017

language of work or name

English

0 references

publication date

1 November 1987

1 reference

23 September 2017

number of pages

5

1 reference

inferred from page(s)

published in

The Lancet

1 reference

23 September 2017

volume

2

1 reference

23 September 2017

issue

8569

1 reference

23 September 2017

page(s)

1165-1169

1 reference

Selective primary health care: strategies for control of disease in the developing world. XX. Typhoid fever.

23 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2887%2991316-X

7 January 2021

Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2887%2991316-X

7 January 2021

Typhoid fever: pathogenesis and immunologic control

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2887%2991316-X

7 January 2021

Reexamination of the protective role of the capsular polysaccharide (Vi antigen) of Salmonella typhi

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2887%2991316-X

7 January 2021

Physicochemical and biological properties of sonically treated Vi antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2887%2991316-X

7 January 2021

Safety and immunogenicity of two Salmonella typhi Vi capsular polysaccharide vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2887%2991316-X

7 January 2021

Typing of typhoid bacilli with Vi bacteriophage; suggestions for its standardisation.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2887%2991316-X

7 January 2021

The pathogenic and immunogenic activities of Salmonella typhi in relation to its antigenic constituents

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2887%2991316-X

7 January 2021

Vaccines against encapsulated bacteria: a global agenda

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2887%2991316-X

7 January 2021

A seven-year field trial of two typhoid vaccines in Guyana

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2887%2991316-X

7 January 2021

A controlled field trial of live Salmonella typhi strain Ty 21a oral vaccine against typhoid: three-year results

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2887%2991316-X

7 January 2021

Failures with oral typhoid vaccine Ty 21a

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2887%2991316-X

7 January 2021

Inefficacy of the commercial live oral Ty 21a vaccine in the prevention of typhoid fever

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2887%2991316-X

7 January 2021

Control of typhoid fever in Bangkok, Thailand, by annual immunization of schoolchildren with parenteral typhoid vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2887%2991316-X

7 January 2021

Second attacks of typhoid fever

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2887%2991316-X

7 January 2021

Reinfection with a different Vi-phage type of Salmonella typhi in an endemic area

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2887%2991316-X

7 January 2021

Clinical Efficacy of Meningococcus Group A Capsular Polysaccharide Vaccine in Children Three Months to Five Years of Age

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2887%2991316-X

7 January 2021

Kinetics of Antibody Production to Group A and Group C Meningococcal Polysaccharide Vaccines Administered during the First Six Years of Life: Prospects for Routine Immunization of Infants and Children

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2887%2991316-X

7 January 2021

Is there a genetic immune defect in families with meningococcal meningitis?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2887%2991316-X

7 January 2021

Mothers of infants with neonatal group B streptococcal septicemia are poor responders to bacterial carbohydrate antigens.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2887%2991316-X

7 January 2021

A NEW ANTIGEN OF B. TYPHOSUS

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2887%2991316-X

7 January 2021

10.1016/S0140-6736(87)91316-X

Identifiers

DOI

1 reference

23 September 2017

1 reference